FOXO4-DRI is a designed senolytic peptide. In cell culture and in mice, it can kill some senescent cells by breaking a FOXO4-p53 survival contact. The published record is almost entirely preclinical. No completed human efficacy trial was identified for this article.
That is the whole claim. Mouse fur, running wheels, serum testosterone, and keloid dishes are not a human aging result. Research-vendor vials are not the investigational peptide used in those papers.
PeptidePrices already tracks FOXO4-DRI listings and a short research profile. This explainer is the evidence map those pages do not carry: what the peptide is, which study designs exist, what the numbers actually measured, and where the human gap still sits.
What FOXO4-DRI is
FOXO4-DRI is a synthetic D-retro-inverso peptide built around the p53-binding stretch of FOXO4, a forkhead transcription factor. The 2017 Cell paper that introduced it fused that motif to an HIV-TAT cell-penetrating sequence so the peptide can enter cells. The STAR Methods list the manufactured sequence as a 46-residue D-amino-acid chain (H-ltlrkepaseiaqsileaysqngwanrrsggkrppprrrqrrkkrg-OH).
D-retro-inverso chemistry reverses the sequence and uses mirror-image amino acids. The Cell authors chose that format because some DRI peptides had already been tested in unrelated human trials, and because the chosen FOXO4 stretch is identical in human and mouse FOXO4 while differing from FOXO1 and FOXO3. That is a design rationale. It is not clinical validation of FOXO4-DRI.
Other names in catalogs include Proxofim and FOXO4 D-retro-inverso peptide. Those labels do not create an approved drug. FOXO4-DRI is not FDA-approved for any indication. It is not a consumer protocol.
Senescent cells are damaged cells that stop dividing but remain metabolically active. They can secrete inflammatory factors called the senescence-associated secretory phenotype, or SASP. Genetic clearance of p16-positive senescent cells can delay aging features in mice. FOXO4-DRI is an attempt to do a similar clearance with a peptide instead of a genetic trick.
How the proposed mechanism works
In senescent fibroblasts, FOXO4 rises and sits in PML bodies next to DNA-SCARS that hold active, Ser15-phosphorylated p53. The Cell group’s working model is that FOXO4 holds that p53 in the nucleus, which favors cell-cycle arrest over apoptosis.
FOXO4-DRI was designed to outcompete FOXO4 for p53. Nuclear magnetic resonance in the 2017 paper showed the peptide reversing p53-induced chemical-shift changes on the FOXO4 forkhead domain, consistent with higher-affinity competition. After uptake, FOXO4-DRI reduced FOXO4/PML/53BP1 foci, lowered p21Cip1, and pushed active p53 out of the nucleus.
The intended kill step is cell-intrinsic apoptosis. In senescent IMR90 fibroblasts, FOXO4-DRI activated caspase-3/7. Knockdown of p53, or pan-caspase blockade, reduced the effect. The same peptide in L-amino-acid form, and an unrelated FOXM1-DRI peptide, did not reproduce the senescent-cell kill.
The signature culture number is a selectivity index of 11.73-fold between senescent and control IMR90 in a viability titration. That is a dish assay on irradiated human fibroblasts. It is not a therapeutic window in people.
A later keloid paper and a 2026 endothelial paper reuse the same FOXO4-p53 nuclear-exclusion story in other cell types. Independent labs can copy a mechanism and still remain in culture and mice.
What the studies actually tested
Four independent primary papers define the public map used here.
Baar et al., Cell, 2017 (Erasmus MC, with Campisi and others). This is the design paper. In culture, ionizing radiation or doxorubicin made IMR90, BJ, and WI-38 fibroblasts senescent. FOXO4-DRI reduced senescent-cell viability more than control-cell viability. In mice carrying a p16::3MR reporter, doxorubicin (10 mg/kg intraperitoneal, twice) raised p16-driven luminescence, liver FOXO4 foci, liver IL-6, body-weight loss, and plasma AST. Three intravenous FOXO4-DRI administrations (5 mg/kg on days 1, 3, and 5) reduced those doxorubicin-linked changes. Fast-aging XpdTTD/TTD mice already had high p16 signal at 26 weeks. FOXO4-DRI lowered that signal, improved a 0-to-4 fur score, lowered abdominal surface temperature (a fur-density proxy), raised responsiveness to gentle stimuli, and increased voluntary running in most treated TTD mice. Baseline running was 1.37 ± 0.54 km/day in TTD mice versus 9.37 ± 1.1 km/day in wild-type mice. In TTD and naturally aged p16::3MR mice, the peptide reduced tubular senescence marks (LMNB1 loss, IL-6) and lowered plasma urea, with creatinine also falling in the naturally aged cohort. Platelet counts were not reduced at day 30 in the reported blood panels. Heart sections from 26-week wild-type mice showed no obvious pathology on the stains used. The authors still called for a more thorough safety analysis.
Zhang et al., Aging, 2020 (Sun Yat-sen University). This group is independent of the Cell authors. In 14 human testis specimens (6 men aged 22-30; 8 men aged 66-87), FOXO4 stained Leydig cells and was more nuclear in the older samples. That is histology, not a FOXO4-DRI treatment of people. In H2O2-treated TM3 Leydig cells, FOXO4-DRI excluded nuclear Ser15-p53 and raised apoptosis in the senescent cultures. In 20-to-24-month-old male mice, three intraperitoneal 5 mg/kg administrations, read at day 30, were followed by higher serum testosterone, higher 3β-HSD and CYP11A1, lower interstitial SA-β-gal, and lower testicular p53, p21, p16, IL-1β, IL-6, and TGF-β (n=6 per arm). Body and testis weights did not differ. The authors wrote that they lacked direct in-vivo proof that senescent Leydig cells were eliminated, and they flagged untested muscle and cardiac risk for systemic use.
Kong et al., Communications Biology, 2025 (Plastic Surgery Hospital, Chinese Academy of Medical Sciences). This group is independent of both earlier labs. Single-cell RNA-seq of keloid versus adjacent skin (n=4 pairs) found more mesenchymal (51% versus 34%) and pro-inflammatory (31% versus 25%) fibroblasts, and more senescence-marker-positive fibroblasts (59.5% versus 36.5%). Keloid tissue had more SA-β-gal and p16. In a serum-limitation culture model, 25 μM FOXO4-DRI for 3 days cut G0/G1 keloid fibroblasts from 90.78% ± 1.62% to 63.68% ± 11.16% and raised apoptotic keloid fibroblasts from 3.31% ± 0.46% to 18.6% ± 9.44% (n=3). Reported IC50 values were 34.19 μM in senescent keloid fibroblasts versus 93.77 μM in non-senescent keloid fibroblasts (2.7-fold). TUNEL-positive cells appeared in keloid organ cultures after FOXO4-DRI. These are explants and dishes from surgical tissue. Patients were not treated with the peptide.
Hu et al., Frontiers in Bioengineering and Biotechnology, 15 January 2026 (Wenzhou Medical University). This group is a fourth independent lab. In 17-month naturally aged mice, FOXO4-DRI was given at 5 mg/kg intraperitoneal every 2 days for 1 month. A separate D-galactose aging model used the same 5 mg/kg schedule for 4 weeks. The paper reports lower aortic aging marks and better aortic function in both mouse models, plus improved function in human umbilical-vein endothelial cells after 50 μM FOXO4-DRI during a 3-hour oxygen-glucose deprivation challenge. Co-immunoprecipitation supported disrupted FOXO4-p53 binding and downstream BAX and cleaved caspase-3. This is still mouse aorta and cultured endothelial cells.
A ClinicalTrials.gov search for FOXO4-DRI, Proxofim, and FOXO4 peptide did not return a registered interventional human trial in the evidence review for this article.
| Paper | Design | What was treated | Human FOXO4-DRI exposure |
|---|---|---|---|
| Baar 2017, Cell | Culture titration plus three mouse models | Irradiated or doxorubicin-senescent fibroblasts; doxorubicin mice; XpdTTD/TTD; naturally aged p16::3MR | None |
| Zhang 2020, Aging | Human histology plus TM3 cells plus aged mice | Leydig-cell FOXO4 location in donated testes; H2O2-senescent TM3; 20-24 month mice | None. Human tissue was observational. |
| Kong 2025, Commun Biol | scRNA-seq, culture, organ culture | Keloid and skin fibroblasts; keloid explants | None. Peptide stayed in the dish. |
| Hu 2026, Front Bioeng Biotechnol | Aged and D-gal mice plus HUVECs | Aorta and endothelial cells | None |
Research doses reported in animals and culture
FOXO4-DRI is not approved for human use. The table reports what laboratories used. It is not a dosage guide and it is not a consumer protocol.
| Setting | Reported exposure | Source |
|---|---|---|
| IMR90 and related fibroblasts | Concentration-response; 25 μM in timed imaging and focus assays | Baar et al., 2017 |
| Doxorubicin and aging mice | 5 mg/kg intravenous, every other day, 3 times (days 1, 3, 5) | Baar et al., 2017 |
| Aged male mice, testosterone arm | 5 mg/kg intraperitoneal, every other day, 3 times; outcomes at day 30 | Zhang et al., 2020 |
| Keloid fibroblast and organ culture | 25 μM for 3 days (organ culture followed through day 10) | Kong et al., 2025 |
| Naturally aged mice, aorta arm | 5 mg/kg intraperitoneal every 2 days for 1 month | Hu et al., 2026 |
| HUVEC oxygen-glucose deprivation | 50 μM during a 3-hour challenge | Hu et al., 2026 |
That does not make 5 mg/kg, 25 μM, or 50 μM an approved dose. Intermittent mouse schedules exist because senolytics are often tested as short clearances, not daily replacement hormones. A research-chemical vial sold as FOXO4-DRI is not the Pepscan-manufactured Cell reagent, and it is not a protocol.
What this does not mean
- It is not human efficacy. No identified trial gave FOXO4-DRI to people and measured a clinical endpoint.
- It is not an approved senolytic drug. FDA has not approved FOXO4-DRI for aging, chemotherapy recovery, hypogonadism, keloids, or vascular disease.
- Mouse fur and urea are not a longevity claim. The Cell phenotypes are fitness proxies in specific strains, including a DNA-repair progeria model.
- Higher testosterone in aged mice is not a treatment for late-onset hypogonadism. Zhang et al. said they did not prove Leydig-cell clearance in vivo and did not time the duration of the testosterone change.
- Keloid explant apoptosis is not a scar therapy. Kong et al. treated tissue in culture.
- Aortic changes in mice are not a cardiovascular indication. Hu et al. remain in animals and HUVECs.
- A research-vendor listing is not the study product. Identity, amount, and sterility can differ. A COA check can test paperwork. It cannot turn a catalog vial into the 2017 investigational peptide.
- This is not medical advice, and it is not a consumer dosing protocol.
The site’s centenarian immune-system roundup already treats FOXO4-DRI as animal-model senolytic work. The RLS-1496 senescent-skin article covers a different, topical senescent-cell program with human skin data FOXO4-DRI does not have.
Limitations
The human gap is the first limitation. Zhang’s testis staining and Kong’s surgical keloids are human tissue. Neither study administered FOXO4-DRI to a living person.
Sample sizes are small. Zhang’s in-vivo arms used 6 mice each. Kong’s culture assays often used n=3. Cell 2017 pooled some urea cohorts at 7-8 mice per treatment and still reported large biological spread in naturally aged p16 reporters.
Safety is incomplete even in mice. The Cell paper did not see thrombocytopenia or obvious heart lesions in the stains and ages tested. Zhang et al. explicitly worried about muscle and cardiac exposure because FOXO4 protein appears in testis, placenta, and muscle in human atlas data. Long-term p53-pathway manipulation, immunogenicity of a D-amino-acid TAT peptide, and off-target effects in low-senescence tissues are open.
Selectivity numbers do not travel. The 11.73-fold IMR90 index and Kong’s 2.7-fold keloid IC50 ratio are different assays, cells, and endpoints. Neither is a human therapeutic index.
Mechanism papers can over-read p53. FOXO4-DRI needs p53 for the Cell apoptosis phenotype. That is a reason to study tumor-suppressor context. It is not evidence of cancer causation or cancer prevention in people.
Commercial FOXO4-DRI is a separate problem. Synthesis of a 46-residue D-peptide is expensive. Catalog strength, salt, and TAT integrity are not established by a mouse paper.
What to watch
- A first-in-human protocol. Until a registered interventional study exists, the compound stays preclinical.
- Peer-reviewed human pharmacodynamics. Culture explants are not pharmacokinetics in patients.
- Independent in-vivo replication outside the original Cell models. Zhang, Kong, and Hu already move the peptide into testis, keloid, and endothelium. Larger, blinded mouse studies would still help.
- Whether later papers keep the 5 mg/kg, three-dose motif or change it. Hu et al. used a month-long every-other-day schedule. That is a different exposure than Cell 2017.
- On-target p53 risk in the next safety package. Platelets and one heart-stain panel are not a toxicology program.
- How vendors describe the peptide. Mechanism language from Cell 2017 is not a purity or sterility claim.
FAQs
What is FOXO4-DRI?
A synthetic D-retro-inverso peptide designed to block FOXO4 binding to p53 and trigger apoptosis in some senescent cells. It is investigational and not FDA-approved.
Has FOXO4-DRI been tested in humans?
No interventional human trial was identified. Published human material is observational testis staining and keloid tissue used in culture, not patient dosing.
Did it reverse aging in mice?
In Cell 2017, selected aging-associated measures moved: fur density, running in most treated TTD mice, and renal filtration markers. Those are mouse phenotypes after a short peptide course. They are not a human aging result.
What dose was used?
Laboratories reported 5 mg/kg in mice and 25 μM or 50 μM in culture. FOXO4-DRI is not approved for human use. That does not make those figures an approved dose or a consumer protocol.
Is a research-vendor vial the same peptide used in Cell 2017?
No. The Cell reagent was a defined manufactured sequence. Catalog listings are a different market. Check lot paperwork; do not treat a vial as a trial product.
Is this a GLP-1 or obesity drug story?
No. FOXO4-DRI is a senolytic research peptide. It is not an incretin agonist and it is not the pemvidutide MASH program published this morning.
This article is for general informational purposes only and is not medical advice. Talk to a licensed clinician about personal medical decisions. FOXO4-DRI is an investigational senolytic peptide studied in cells and mice. Nothing here is a dosing protocol, an availability claim, or a recommendation to obtain an unapproved product.
Continue your research
- FOXO4-DRI price and vendor comparison
- FOXO4-DRI research profile
- Centenarian immune system and where senolytic peptides fit
- RLS-1496 and senescent-skin research
- COA Authenticity Checker
- How to verify a peptide COA
Sources
- Baar MP, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell. 2017
- Zhang C, et al. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY). 2020
- Kong YX, et al. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Commun Biol. 2025
- Hu Z, et al. FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway. Front Bioeng Biotechnol. 15 January 2026